Monoclonal antibody · Antagonist of CD3 epsilon (CD3E) · developed by Tiziana Life Sciences
Foralumab is a monoclonal antibody against CD3 epsilon that binds to T cells and prevents T cell activation, suppressing immune responses. It is administered intranasally and is studied in Alzheimer's disease, mild cognitive impairment, multiple sclerosis, and multiple system atrophy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06489548 | Phase 2 | Dementia | Recruiting | TLSA |
| NCT06868628 | Phase 2 | Multiple System Atrophy | Recruiting | TLSA |
| NCT06890923 | Phase 2 | Non-Active Secondary Progressive Multiple Sclerosis | Recruiting | TLSA |
| NCT06292923 | Phase 2 | Secondary Progressive Multiple Sclerosis | Active not recruiting | TLSA |
| NCT05029609 | Phase 1 | Primary Progressive Multiple Sclerosis | Withdrawn | TLSA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alzheimers DiseaseDementiaMild Cognitive Impairment Due to Alzheimer's DiseaseMultiple System AtrophyNon-Active Secondary Progressive Multiple SclerosisMultiple SclerosisPrimary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis
Updated Oct 3, 2026. Something wrong or missing? Report it on the TLSA page.
See TLSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TLSA catalysts and pipeline →